Identification of Potential Biomarkers Associated with Basal Cell Carcinoma

Abstract

Purpose. This work is aimed at identifying several molecular markers correlated with the diagnosis and development of basal cell carcinoma (BCC). Methods. The available microarray datasets for BCC were obtained from the Gene Expression Omnibus (GEO) database, and differentially expressed genes (DEGs) were identified between BCC and healthy controls. Afterward, the functional enrichment analysis and protein-protein interaction (PPI) network analysis of these screened DEGs were performed. An external validation for the DEG expression level was also carried out, and receiver operating characteristic curve analysis was used to evaluate the diagnostic values of DEGs. Result. In total, five microarray datasets for BCC were downloaded and 804 DEGs (414 upregulated and 390 downregulated genes) were identified. Functional enrichment analysis showed that these genes including CYFIP2, HOXB5, EGFR, FOXN3, PTPN3, CDC20, MARCKSL1, FAS, and PTCH1 were closely correlated with the cell process and PTCH1 played central roles in the BCC signaling pathway. Moreover, EGFR was a hub gene in the PPI network. The expression changes of six genes (CYFIP2, HOXB5, FOXN3, PTPN3, MARCKSL1, and FAS) were validated by an external GSE74858 dataset analysis. Finally, ROC analysis revealed that CYFIP2, HOXB5, PTPN3, MARCKSL1, PTCH1, and CDC20 could distinguish BCC and healthy individuals. Conclusion. Nine gene signatures (CYFIP2, HOXB5, EGFR, FOXN3, PTPN3, CDC20, MARCKSL1, FAS, and PTCH1) may serve as promising targets for BCC detection and development.

Circulating extracellular vesicle-derived MARCKSL1 is a potential diagnostic non-invasive biomarker in metastatic colorectal cancer patients

“…As a protein associated with the occurrence and development of various tumors, MARCKSL1 has been mainly verified as a potential tumor marker or a new therapeutic target in lung cancer 21 – 24 , liver cancer 25 – 27 , colorectal cancer and other tumors. In addition, there are ongoing studies on prostate cancer 28 , breast cancer 29 , 30 , esophageal cancer 31 , basal cell carcinoma 32 , squamous cell carcinoma 33 and other tumors, and their potential as markers is gradually attracting the attention of researchers. MARCKSL1 has been selected as a potential marker for distinguishing metastatic and nonmetastatic sporadic colorectal cancer (sCRC) and is highly expressed in patients with metastatic sCRC.…”

Cyfip2 controls the acoustic startle threshold through FMRP, actin polymerization, and GABABreceptor function

“…Through its ability to modulate both the actin cytoskeleton and protein translation, Cyfip2 is well-positioned to be a critical factor for many processes in neurodevelopment [33,34,[37][38][39]45,49]. Further highlighting its importance, Cyfip2 has been implicated in an array of neuropsychiatric and other conditions, including schizophrenia [62], autism [49,[63][64][65], binge eating [66][67][68], obesity [69], amyotrophic lateral sclerosis (ALS) [70,71], Alzheimer's disease [72], epilepsy [65,[73][74][75][76], and cancer [77][78][79][80][81][82]. Here we focused on Cyfip2's role in a common endophenotype of schizophrenia and autism, increased acoustic startle responsiveness [4,24,27,28].…”

Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC

“…While numerous studies have been conducted on the genetic markers of BCC and PDAC individually (Pellegrini et al, 2017) (Liu et al, 2020) (Tang et al, 2018) (Kunovsky et al, 2018), we present here the first direct comparison between the expression patterns of malignant cells in the two cancers (Figure 3B). We find that unsurprisingly keratins (namely KRT5, KRT14, and KRT17) which are marker genes for keratinocytes are overexpressed in BCC compared to PDAC by approximately an order of magnitude.…”